New Therapies for Hyperkalemia Across the Continuum of Care

Slides:

Advertisements

Similar presentations

Prior Trials of RAAS Inhibitors

Advertisements

Emerging Concepts in Heart Failure

Current State of Hyperkalemia Management

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.

Advances in Managing Inhibitors in Patients With Hemophilia A

Acute Heart Failure.

Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Updates Abound in Hyperkalemia Management

Unmet Needs in the Secondary Prevention in ACS

Metastatic Renal Cell Carcinoma

PCP Perspectives Clinical Considerations in Hyperkalemia

Case Challenges in Chronic Migraine

What Do We Know About LDL-C?

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

Managing Depression in Bipolar I Disorder

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Checkpoint Inhibition

Diagnostic and Management Challenges in Patients With Chronic Migraine

HCV Protease Inhibitors in Clinical Practice

Exploring Emerging Treatments for Hyperkalemia

Understanding PAD.

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Managing Adverse Events With New Oral Therapies in CLL

Mutational Testing to Select Novel Targeted Therapies in AML

Multidisciplinary Management of Hyperkalemia:

Hyperkalemia in the Hospital

Personalizing Management in the Care of Patients With Advanced Sarcoma

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Shifting Currents in Hyperkalemia Management 2015 in Review

Shifting Currents in Hyperkalemia Management 2015 in Review

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

When Is Intrathecal Drug Delivery Appropriate?

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Cancer-Associated Thrombosis

CAD and HF Often Coexist

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Patient Questions and Expert Answers in Psoriasis:

HCV Protease Inhibitors in Clinical Practice

Managing Pulmonary Embolism Posthospital Discharge

LDL Cholesterol.

Proteasome Inhibitors and Patients

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Improving Adherence to Antiplatelet Therapy After an ACS Event

Assessing the Burden of Hyperkalemia

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Breaking Down the Data in Hyperkalemia

Educational Objectives

New Lipid-Lowering Therapies

When Is Intrathecal Drug Delivery Appropriate?

2015 EASD In Review: CV Risk management in t2dm

AMD Therapy: Where Are We Now and Where Are We Going?

Assessing the Burden of Hyperkalemia

Third-Generation EGFR TKIs

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Diagnostic Criteria Migraine Without Aura

Clinical Comparisons.

RAASi Enabling in the Modern Era

Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.

The causes and treatment of hyperkalemia across the continuum of kidney function and with kidney replacement therapies. The causes and treatment of hyperkalemia.

Potassium Situations Resolved

Management of NTM Lung Disease

Presentation transcript:

New Therapies for Hyperkalemia Across the Continuum of Care

Overview of Hyperkalemia

RAAS Inhibitor Use and Risk of Hyperkalemia

Diagnostic Workup Causes of Hyperkalemia

Diagnostic Workup Electrocardiographic Features

Acute Treatment of Hyperkalemia

Increasing Incidence of Hyperkalemia

Dietary Management of Hyperkalemia

Management of Chronic Hyperkalemia Before Era of New K+ Binders

SPS

Challenges of Hyperkalemia in At-Risk Patients

Summary

New K+ Binder Patiromer

Efficacy of Patiromer Maintains Normal K+ Levels Up to 1 Year

Emerging K+ Binder Sodium Zirconium Cyclosilicate (ZS-9)

Efficacy of ZS-9 During 48-h Induction Phase in HARMONIZE

HARMONIZE Efficacy During Randomized Phase

ZS005 Interim Results ZS-9 Maintains Normal K+ Levels Up to 1 Year

K+ and Na+ Concentrations in the GI Tract

SPS (cont)

SPS Plus Sorbitol vs Sorbitol Alone

New K+ Binders Adverse Events

Comparison of SPS, Patiromer, and ZS-9

New K+ Binders as Preventative Therapy

Closing Comments

Abbreviations